Companies → Day One Biopharmaceuticals, Inc

Save to list

Remove

Day One Biopharmaceuticals, Inc

United States, Brisbane

Report a bug?

Claim ownership and edit

Description

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Industries

Wood Product Manufacturing

SIC

Lumber and Wood Products, Except Furniture

Address:

1800 Sierra Point Parkway

Website:

dayonebio.com

Revenue

Recent news:

Wall Street Analysts Issue Series of Rating Changes for Key Stocks

Summary of recent analyst rating changes from major financial firms, detailing key upgrades and downgrades across various sectors including technology, consumer goods, and healthcare.

Source: IndexBox Mar 11, 2026

Wall Street Analysts Issue New Stock Ratings & Price Targets

Overview of recent analyst rating changes including upgrades for Rivian, CrowdStrike, and Teladoc, and downgrades for Qualcomm and Novo Nordisk, based on demand projections, market positioning, and valuation.

Source: IndexBox Mar 10, 2026

Trading Volume Leaders: Peraso, BigBear.ai, Trio Petroleum Lead Market Activity

A summary of the highest trading volume stocks across major U.S. exchanges, detailing key leaders on Nasdaq, NYSE, and NYSE American, along with notable price gains and declines.

Source: IndexBox Mar 7, 2026

XNAS - Delayed Quote - USD

DAWN

21.44 +0.05 (+0.23%)

At close March 22 23:14 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 06/22/2025

Market Cap: 640.61 M

Enterprise Value: 170.51 M

Trailing P/E: N/A

Forward P/E: -5.64

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): 3.80

Price/Book (mrq): 1.34

Enterprise Value/Revenue: 1.05

Enterprise Value/EBITDA: -0.90

Financial Highlights

Profitability and Income Statement

Profit Margin: -42.66%

Return on Assets (ttm): -27.81%

Return on Equity (ttm): -17.80%

Revenue (ttm): 161.92 M

Net Income Avi to Common (ttm): -69.08 M

Diluted EPS (ttm): -0.65

Balance Sheet and Cash Flow

Total Cash (mrq): 473.02 M

Total Debt/Equity (mrq): 0.61%

Levered Free Cash Flow (ttm): -155.79 M

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.